LH Stock Recent News

Labcorp® Plasma CompleteTM offers oncologists a highly sensitive and specific genomic profiling solution from a simple blood draw BURLINGTON, N.C. , Feb. 24, 2025 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the clinical availability of Labcorp® Plasma CompleteTM , a circulating tumor DNA (ctDNA)-based comprehensive genomic profiling solution for patients with advanced solid tumors.

Thursday, Laboratory Corp (NYSE: LH) reported fourth-quarter 2024 adjusted earnings per share of $3.45, up from $3.30 a year ago, beating the consensus of $3.39.

Although the revenue and EPS for Labcorp (LH) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Labcorp (LH) came out with quarterly earnings of $3.45 per share, beating the Zacks Consensus Estimate of $3.40 per share. This compares to earnings of $3.30 per share a year ago.

In the fourth quarter of 2024, LH is likely to have witnessed strong growth in both diagnostics and biopharma laboratory services.

Labcorp (LH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

BURLINGTON, N.C. , Jan. 8, 2025 /PRNewswire/ -- Labcorp Holdings Inc. (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today that its Board of Directors has declared a cash dividend of $0.72 per share of common stock.